OncoMatch/Clinical Trials/NCT06075810

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

Is NCT06075810 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MBQ-167 for breast cancer.

Phase 1RecruitingMBQ PharmaNCT06075810Data as of May 2026

Treatment: MBQ-167 — A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Precision Next Gen Oncology & Research Center · Beverly Hills, California
Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI · Sarasota, Florida
Sarah Cannon Research Institute/SCRI · Nashville, Tennessee

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify